Neuroimmunophilin ligands: evaluation of their therapeutic potential for the treatment of neurological disorders
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Neuroimmunophilin ligands are a class of compounds that hold great promise for the treatment of nerve injuries and neurological disease. In contrast to neurotrophins (e.g., nerve growth factor), these compounds readily cross the blood-brain barrier, being orally effective in a variety of animal models of ischaemia, traumatic nerve injury and human neurodegenerative disorders. A further distinction is that neuroimmunophilin ligands act via unique receptors that are unrelated to the classical neurotrophic receptors (e.g., trk), making it unlikely that clinical trials will encounter the same difficulties found with the neurotrophins. Another advantage is that two neuroimmunophilin ligands (cyclosporin A and FK-506) have already been used in humans (as immunosuppressant drugs). Whereas both cyclosporin A and FK-506 demonstrate neuroprotective actions, only FK-506 and its derivatives have been clearly shown to exhibit significant neuroregenerative activity. Accordingly, the neuroprotective and neuroregenerative properties seem to arise via different mechanisms. Furthermore, the neuroregenerative property does not involve calcineurin inhibition (essential for immunosuppression). This is important since most of the limiting side effects produced by these drugs arise via calcineurin inhibition. A major breakthrough for the development of this class of compounds for the treatment of human neurological disorders was the ability to separate the neuroregenerative property of FK-506 from its immunosuppressant action via the development of non-immunosuppressant (non-calcineurin inhibiting) derivatives. Further studies revealed that different receptor subtypes, or FK-506-binding proteins (FKBPs), mediate immunosuppression and nerve regeneration (FKBP-12 and FKBP-52, respectively, the latter being a component of steroid receptor complexes). Thus, steroid receptor chaperone proteins represent novel targets for future drug development of novel classes of compounds for the treatment of a variety of human neurological disorders, including traumatic injury (e.g., peripheral nerve and spinal cord), chemical exposure (e.g., vinca alkaloids, Taxol) and neurodegenerative disease (e.g. , diabetic neuropathy and Parkinson's disease).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Specific incorporation of cyclophilin A into HIV-1 virions
Franke, E. K., Yuan, H. E. H., & Luban, J. (1994) · Nature · doi:10.1038/372359a0 · Cited by 745
HSP56: a novel heat shock protein associated with untransformed steroid receptor complexes
Sanchez, E. R. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45667-0 · Cited by 214
Silverstein, A. M., Galigniana, M. D., Kanelakis, K. C., Radanyi, C., Renoir, J.-M., & Pratt, W. B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.52.36980 · Cited by 186
Cited by
Importance of microbial natural products and the need to revitalize their discovery
Demain, A. L. (2014) · Journal of Industrial Microbiology and Biotechnology · doi:10.1007/s10295-013-1325-z · Cited by 433
Soumyanath, A., Zhong, Y.-P., Yu, X., Bourdette, D., Koop, D. R., Gold, S. A., & Gold, B. G. (2005) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.57.9.0018 · Cited by 150
Self-citationAdvances in small molecules promoting neurotrophic function
PRICE, R., MILNE, S., SHARKEY, J., & MATSUOKA, N. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.03.005 · Cited by 148
Targeting FKBP isoforms with small-molecule ligands
Blackburn, E. A., & Walkinshaw, M. D. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.04.007 · Cited by 73
Metadata
- Authors
- Gold, B. G.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 2000-10
- Volume
- 9
- Issue
- 10
- Pages
- 2331-2342
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2113100908
- Cited by
- 141
- References
- 3
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.